Microbix takes over urokinase production from Genpharm
Negotiations for the exclusive right to manufacture the drug for a new proprietary use
In addition to producing urokinase at the facilities, Microbix plans to use the plant to manufacture other products. Microbix' original intent was to market its urokinase product, the 'clot busting' drug ThromboClear(TM), as a generic equivalent. While several important milestones have already been achieved, the Company has been reviewing its strategy because of slowing sales for the brand-name drug after the manufacturer announced that it was no longer producing the product.
As a result of this renewed strategy, Microbix has now entered into negotiations for exclusive rights to manufacture the drug for a specific new proprietary use. Details will be announced if and when negotiations are successfully concluded.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.